Purified exosome product - RION
Alternative Names: 10% PEP; 20% PEP; PEP; PEP Biologic™; PEPTM; Purified Exosome ProductTMLatest Information Update: 06 Jul 2026
At a glance
- Originator Mayo Foundation for Medical Education and Research
- Developer Mayo Foundation for Medical Education and Research; RION
- Class Blood products and substitutes; Exosome therapies
- Mechanism of Action Angiogenesis inducing agents; Exosome replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic foot ulcer
- Phase I Osteoarthritis
- No development reported Alopecia; Joint disorders; Urinary incontinence; Wounds
- Discontinued Crohn's disease
Most Recent Events
- 01 Jul 2026 Purified exosome product - RION receives Breakthrough Therapy status for Diabetic foot ulcer in USA
- 01 Jul 2026 INTENT Biologics plans a phase III trial for Diabetic foot ulcer
- 28 Mar 2026 No recent reports of development identified for preclinical development in Alopecia in USA (Parenteral, Injection)